FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136295087> ?p ?o ?g. }

• W2136295087 endingPage "455" @default.
• W2136295087 startingPage "447" @default.
• W2136295087 abstract "Despite the efficacy of statins in lowering low-density lipoprotein cholesterol (LDL-C) levels, many patients who are at high risk for heart disease with hypercholesterolemia require additional LDL-C level reduction. The cholesterol absorption inhibitor, ezetimibe, has been shown to provide significant incremental reductions in LDL-C levels when co-administered with statins. This study was performed to compare the efficacy and safety of ezetimibe (10 mg) plus response-based atorvastatin titration versus response-based atorvastatin titration alone in the attainment of LDL-C goals in subjects who are at high risk for coronary heart disease (CHD) and are not at their LDL-C goal on the starting dose of atorvastatin.This was a 14-week, multicenter, randomized, double-blind, active-controlled study conducted in 113 clinical research centers in 21 countries. Participants were adults with heterozygous familial hypercholesterolemia (HeFH), CHD, or multiple (> or =2) cardiovascular risk factors, and a LDL-C level > or =130 mg/dL after a 6- to 10-week dietary stabilization and atorvastatin (10 mg/day) open-label run-in period. Eligible subjects continued to receive atorvastatin (10 mg) and were randomized to receive blinded treatment with ezetimibe (10 mg/day; n = 305) or an additional 10 mg/day of atorvastatin (n = 316). The atorvastatin dose in both groups was doubled after 4 weeks, 9 weeks, or both when the LDL-C level was not at its goal (< or =100 mg/dL), so that patients receiving combined therapy could reach 40 mg/day and patients receiving atorvastatin alone could reach 80 mg/day. The primary end point was the proportion of subjects achieving their LDL-C level goal at week 14. A secondary end point was the change in LDL-C level and other lipid parameters at 4 weeks after ezetimibe co-administration with 10 mg/day of atorvastatin versus 20 mg/day of atorvastatin monotherapy.The proportion of subjects reaching their target LDL-C level goal of < or =100 mg/dL was significantly higher in the co-administration group than in the atorvastatin monotherapy group (22% vs 7%; P <.01). At 4 weeks, levels of LDL-C, triglycerides, and non-high-density lipoprotein cholesterol were reduced significantly more by combination therapy than by doubling the dose of atorvastatin (LDL-C -22.8% versus -8.6%; P <.01). The combination regimen had a safety and tolerability profile similar to that of atorvastatin alone.The addition of ezetimibe to the starting dose of 10 mg/day of atorvastatin followed by response-based atorvastatin dose titration to a maximum of 40 mg/day provides a more effective means for reducing LDL-C levels in patients at high risk for CHD than continued doubling of atorvastatin as high as 80 mg/day alone." @default.
• W2136295087 created "2016-06-24" @default.
• W2136295087 creator A5003940856 @default.
• W2136295087 creator A5029206998 @default.
• W2136295087 creator A5049272753 @default.
• W2136295087 creator A5067906247 @default.
• W2136295087 creator A5072424638 @default.
• W2136295087 creator A5072747894 @default.
• W2136295087 creator A5072793703 @default.
• W2136295087 creator A5078279057 @default.
• W2136295087 creator A5084834521 @default.
• W2136295087 creator A5086404218 @default.
• W2136295087 date "2004-09-01" @default.
• W2136295087 modified "2023-10-16" @default.
• W2136295087 title "Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin" @default.
• W2136295087 cites W1607855941 @default.
• W2136295087 cites W1844308307 @default.
• W2136295087 cites W1983422922 @default.
• W2136295087 cites W1984067430 @default.
• W2136295087 cites W1987507883 @default.
• W2136295087 cites W1993652095 @default.
• W2136295087 cites W1995116750 @default.
• W2136295087 cites W1995187774 @default.
• W2136295087 cites W2015503831 @default.
• W2136295087 cites W2024334311 @default.
• W2136295087 cites W2111385165 @default.
• W2136295087 cites W2118310760 @default.
• W2136295087 cites W2123050824 @default.
• W2136295087 cites W2124938579 @default.
• W2136295087 cites W2140072878 @default.
• W2136295087 cites W2149823862 @default.
• W2136295087 cites W2152789823 @default.
• W2136295087 cites W2168876694 @default.
• W2136295087 cites W2741033020 @default.
• W2136295087 cites W4238251256 @default.
• W2136295087 cites W424467158 @default.
• W2136295087 cites W4361972733 @default.
• W2136295087 cites W81463456 @default.
• W2136295087 doi "https://doi.org/10.1016/j.ahj.2004.03.052" @default.
• W2136295087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15389231" @default.
• W2136295087 hasPublicationYear "2004" @default.
• W2136295087 type Work @default.
• W2136295087 sameAs 2136295087 @default.
• W2136295087 citedByCount "156" @default.
• W2136295087 countsByYear W21362950872012 @default.
• W2136295087 countsByYear W21362950872013 @default.
• W2136295087 countsByYear W21362950872014 @default.
• W2136295087 countsByYear W21362950872015 @default.
• W2136295087 countsByYear W21362950872016 @default.
• W2136295087 countsByYear W21362950872017 @default.
• W2136295087 countsByYear W21362950872018 @default.
• W2136295087 countsByYear W21362950872019 @default.
• W2136295087 countsByYear W21362950872020 @default.
• W2136295087 countsByYear W21362950872021 @default.
• W2136295087 countsByYear W21362950872022 @default.
• W2136295087 crossrefType "journal-article" @default.
• W2136295087 hasAuthorship W2136295087A5003940856 @default.
• W2136295087 hasAuthorship W2136295087A5029206998 @default.
• W2136295087 hasAuthorship W2136295087A5049272753 @default.
• W2136295087 hasAuthorship W2136295087A5067906247 @default.
• W2136295087 hasAuthorship W2136295087A5072424638 @default.
• W2136295087 hasAuthorship W2136295087A5072747894 @default.
• W2136295087 hasAuthorship W2136295087A5072793703 @default.
• W2136295087 hasAuthorship W2136295087A5078279057 @default.
• W2136295087 hasAuthorship W2136295087A5084834521 @default.
• W2136295087 hasAuthorship W2136295087A5086404218 @default.
• W2136295087 hasConcept C126322002 @default.
• W2136295087 hasConcept C168563851 @default.
• W2136295087 hasConcept C2777482532 @default.
• W2136295087 hasConcept C2778163477 @default.
• W2136295087 hasConcept C2778657065 @default.
• W2136295087 hasConcept C2779120738 @default.
• W2136295087 hasConcept C71924100 @default.
• W2136295087 hasConcept C90924648 @default.
• W2136295087 hasConcept C98274493 @default.
• W2136295087 hasConceptScore W2136295087C126322002 @default.
• W2136295087 hasConceptScore W2136295087C168563851 @default.
• W2136295087 hasConceptScore W2136295087C2777482532 @default.
• W2136295087 hasConceptScore W2136295087C2778163477 @default.
• W2136295087 hasConceptScore W2136295087C2778657065 @default.
• W2136295087 hasConceptScore W2136295087C2779120738 @default.
• W2136295087 hasConceptScore W2136295087C71924100 @default.
• W2136295087 hasConceptScore W2136295087C90924648 @default.
• W2136295087 hasConceptScore W2136295087C98274493 @default.
• W2136295087 hasIssue "3" @default.
• W2136295087 hasLocation W21362950871 @default.
• W2136295087 hasLocation W21362950872 @default.
• W2136295087 hasOpenAccess W2136295087 @default.
• W2136295087 hasPrimaryLocation W21362950871 @default.
• W2136295087 hasRelatedWork W2023920086 @default.
• W2136295087 hasRelatedWork W2047344526 @default.
• W2136295087 hasRelatedWork W2131855630 @default.
• W2136295087 hasRelatedWork W2284842420 @default.
• W2136295087 hasRelatedWork W2623387503 @default.
• W2136295087 hasRelatedWork W2743967130 @default.
• W2136295087 hasRelatedWork W2780689692 @default.
• W2136295087 hasRelatedWork W3204512944 @default.
• W2136295087 hasRelatedWork W4229489358 @default.

• next